Nω-Nitro-Nω′-Substituted Guanidines: A Simple Class of Nitric Oxide Synthase Inhibitors

Christophe D. Guillon1, David D. Wisnoski1, Jaya Saxena1, Ned D. Heindel1, Diane E. Heck2, Donald J. Wolff3, Jeffrey D. Laskin4

1Department of Chemistry, Lehigh University, Bethlehem, USA
2Department of Environmental Health Science, New York Medical College, Valhalla, USA
3Department of Pharmacology, Rutgers University—Robert Wood Johnson Medical School, Piscataway, USA
4Department of Environmental and Occupational Medicine, Rutgers University—Robert Wood Johnson Medical School, Piscataway, USA
Email: chg3@lehigh.edu

Received 27 March 2014; revised 20 April 2014; accepted 28 April 2014

Copyright © 2014 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract

A series of Nω-nitro-Nω′-substituted guanidines has been prepared as potential inhibitors of the human Nitric Oxide Synthase (NOS) isoforms. The reported utility of amino-guanidine and nitro-arginine in iNOS inhibition points to a potential similar utility for analogs of nitro-guanidine. The compound library was tested against the three isoforms of Nitric Oxide Synthase (eNOS, iNOS and nNOS). Several candidates showed excellent activity and good selectivity for nNOS. One particular compound even demonstrated good selectivity for iNOS. The potential usefulness of such selective inhibitors is discussed.

Keywords

Nitro-Guanidines, Nitric Oxide Synthase (NOS), Isoforms, Selective Inhibitors

1. Introduction

Nitric oxide (NO) is a key messenger involved in a wide range of biochemical processes [1]. Its role is crucial for a number of physiological functions and many pathologies can be related to its inadequate release or over-production [2] [3]. NO is produced from the oxidation of L-arginine to citrulline [4]. The family of enzymes that catalyze this process is called Nitric Oxide Synthase (NOS) [5] and three different isoforms exist [6]. Two are
constitutive forms, eNOS (e for endothelial, also known as NOS III) involved in the regulation of smooth muscle relaxation, blood pressure and inhibition of platelet aggregation [7]; and nNOS (n for neuronal, also known as NOS I), related to neurotransmission and long-term potentiation [8]. The other isoform iNOS (i for induced, also known as NOS II) is involved in regulation of the immune system and inflammatory responses [9]. These three isoforms have unique roles in separate tissues thus making selective inhibition of either form a suitable strategy for the treatment of specific pathologies. Substantial drug development has been carried out to achieve specific inhibition of the nNOS form as a way to treat strokes and of iNOS for the treatment of septic shock and arthritis. The eNOS form, because of its important role in blood flow regulation, is seldom a clinical therapeutic target. This research has led to the discovery of a number of iNOS and to several nNOS selective inhibitors [1]. However, there is a continuing need for new potent and selective inhibitors of either form of the enzyme as diverse pathologies are found to be linked to these enzymes. Recent work in our laboratories has shown that iNOS inhibitors, such as aminoguanidine (KI = 830 μM), attenuate inflammation in the rat lung induced by the toxic vesicant, nitrogen mustard [10]. In fact, aminoguanidine abrogated nitrogen mustard-induced injury and oxidative stress and inflammation at 1d and 3d post exposure [11].

This finding prompted us to synthesize nitro-guanidine derivatives that displayed increased activity towards iNOS, and indeed two compounds were identified (e.g., compounds 12 and 4). Unexpectedly, most of the other compounds in this library were better nNOS and/or eNOS inhibitors. Although these latter candidates may not be selective for iNOS, they may still suppress the toxicity mediated by iNOS. Moreover, the fact that we have been able to identify nitro-guanidines which are selective for nNOS or eNOS suggests that these may be useful for pathological conditions where suppressing these isoforms of NOS may be beneficial. Other workers are pursuing selective nNOS inhibitors for therapeutic intervention in neuromuscular disorders [12] and neurodegenerative pathologies such as Alzheimer’s and Parkinson’s disease [13] [14]. A number of those known inhibitors are analogs of the substrate L-arginine and include, in particular, N-nitro-arginine [15] [16]. Some of them achieved not only good activity but also demonstrated excellent iNOS selectivity. Our work focused on the preparation of non-amino-acid guanidine-based analogs of Nω-nitro-arginine which has been reported to have about a 250-fold selectivity for nNOS versus iNOS [14].

2. Discussion and Results

2.1. Chemistry

All the compounds prepared were synthesized through a pathway adapted from a process originally developed for the preparation of nitro-guanidines as potential fertilizers [17]-[19]. In such an approach, a commercially available reactive nitroso compound (1-methyl-3-nitro-1-nitrosoguanidine) was used to prepare the target products, as solids, in a convenient one step reaction (Scheme 1). In general, the yields ranged from 33% to 95% and for most compounds were usually greater than 60%. The details of the compounds synthesized are presented in Table 1. When the purity of the crude compounds did not prove satisfactory, as assessed by 1H NMR, they were easily crystallized from a number of solvents such as methanol or methanol/chloroform. Low yields (<20%) were obtained when the reacting amines were poor nucleophiles [15] [16] but the compounds could nonetheless be isolated in sufficient amounts to be tested in the NOS assays even in those cases. The purity of all those compounds was assessed by conventional analytical methods to be greater than 98%.

2.2. Biology

Once isolated and characterized, all the compounds were submitted to NOS screening for which the isolated isoforms of the enzyme were used (iNOS, nNOS and eNOS). The data obtained is summarized in Table 2. Compounds 4, 8, 12, 13, 14, 15, 17, 18 and 27 demonstrated single digit micromolar activities against one or
Table 1. $N_\omega$-nitro-$N_\omega'$-substituted guanidines synthesized according to Scheme 1.

<table>
<thead>
<tr>
<th>Cpd #</th>
<th>$R'$ =</th>
<th>Cpd #</th>
<th>$R'$ =</th>
<th>Cpd #</th>
<th>$R'$ =</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>EtNH-</td>
<td>11</td>
<td>F$_3$C</td>
<td>21</td>
<td>N$_\omega$-</td>
</tr>
<tr>
<td>2</td>
<td>nPrNH-</td>
<td>12</td>
<td>F</td>
<td>22</td>
<td>N$_\omega$-</td>
</tr>
<tr>
<td>3</td>
<td>nBuNH-</td>
<td>13</td>
<td>NH</td>
<td>23</td>
<td>O</td>
</tr>
<tr>
<td>4</td>
<td>F,CCH$_3$NH-</td>
<td>14</td>
<td>NH</td>
<td>24</td>
<td>O</td>
</tr>
<tr>
<td>5</td>
<td>F$_2$CCF$_2$CH$_2$NH-</td>
<td>15</td>
<td>NH</td>
<td>25</td>
<td>N$_\omega$-</td>
</tr>
<tr>
<td>6</td>
<td>F$_2$(CF$_2$)$_2$CH$_2$NH-</td>
<td>16</td>
<td>NH</td>
<td>26</td>
<td>N$_\omega$-</td>
</tr>
<tr>
<td>7</td>
<td>17</td>
<td>NH</td>
<td>27</td>
<td>F</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>18</td>
<td>NH</td>
<td>28</td>
<td>Me</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>19</td>
<td>NH</td>
<td>29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>F$_3$C</td>
<td>20</td>
<td>N$_\omega$-</td>
<td>30</td>
<td>N$_\omega$-</td>
</tr>
</tbody>
</table>

several of the NOS isoforms. In particular 1-nitro-3-(pyridin-3-yl) guanidine (15) proved active against both eNOS (0.3 $\mu$M) and nNOS (0.5 $\mu$M). As far as selectivity is concerned, we were able to identify a number of compounds displaying nNOS selectivity. One such compound, 1-((5-methylthiophen-2-yl)methyl)-3-nitroguanidine (28), although of marginal potency, nevertheless showed selectivity toward nNOS (eNOS/nNOS = 35). It is to be noted that the same compound also demonstrated nNOS over iNOS selectivity (iNOS/nNOS = 30). To a smaller extent, compounds 9 and 10 also showed nNOS selectivity with eNOS to nNOS ratios of 15 and 13 respectively. Although it was not the primary focus of this study, we also herein report some impressive nNOS over iNOS selectivity with compounds 2, 13 and 15 displaying iNOS to nNOS ratio of 62, 50 and 100 respectively. Compound 4, which had the lowest across-the-board inhibition IC$_{50}$’s for all three NOS isoforms (see Table 2), was tested topically for inflammation suppression in a standard mustard-induced inflamed mouse ear vesicant model [20]. In this assay 4 showed 41% suppression of inflammation compared to classic anti-inflammatory standards such as S-naproxen (11%), diclofenac (17%), indomethacin (46%), menthol (53%), or farnesol (64%) [21]. These simple guanidine mimics of the natural substrate of the enzyme, L-arginine, demonstrate that the amino acid portion of that substrate is not required to achieve activity and even selectivity toward the nNOS isoform. Guanidines can be considered a potential platform from which a more in depth SAR could be built and one that could yield even better inhibitors.
3. Conclusion

We have prepared a series of Nω-nitro-Nω'-substituted guanidines in a convenient one step reaction. Evaluation of their inhibitory activity against the isoforms of NOS led to the identification of a number of hits with micromolar and one (15) with sub-micromolar potency. Among those hits, several also demonstrated selectivity toward nNOS (9, 10, 28 nNOS over eNOS selectivity and 2, 13, 15 and 28 for nNOS over iNOS selectivity).
most promising compound of this family (15) could be considered a lead candidate for further development of potent nNOS inhibitors in the class. As potential iNOS inhibitors for use in our mustard-induced lung damage model, 4, 5, 9, 12, and 15 were substantially more potent than aminoguanidine with 12 having the best margin of safety for minimal cross reactivity with nNOS and eNOS. When comparing the activities of the pyridine-containing compounds in this set, i.e., 15, 16, 17, and 18, it is compound 15 for which external hydrogen-bonding (both H-donor and H-acceptor) is the most probable, which has the greatest inhibition of all three isoforms. Recent crystal structure studies have claimed that precisely such external hydrogen bonding by twisted 2-amino-pyridines makes these molecules important pharmacophores in inhibition of nNOS and eNOS [22].

4. Experimental Section

4.1. Chemistry

$^1$H NMR spectra were recorded at 360 MHz and 500 MHz on a Bruker AMX-360 and DRX-500 spectrometer respectively. Chemical shifts were measured relative to CDCl$_3$ ($\delta = 7.24$), CD$_2$OD ($\delta = 3.33$) or acetone-d$_6$ ($\delta = 2.04$) for $^1$H and expressed indirectly in relation to TMS. The following abbreviations are used to describe the signal multiplicity: s (singulet), d (doublet), t (triplet), q (quadruplet) and m (multiplet). Chemical shifts are expressed in ppm and listed as follow: shift in ppm (multiplicity, coupling constant, and attribution). IR Spectra were recorded on a Mattson Polaris FT-IR spectrophotometer as NaCl discs for the crystalline samples. Thin-layer chromatography (TLC) were performed with plates (0.25 mm) pre-coated with fluorescent silica gel. Reaction components were then visualized under UV light and/or with iodine and/or with a saturated solution of KMnO$_4$ in aqueous NaOH (1N). Silica gel (230 - 400 mesh) was used for flash chromatography separations.

Retention compounds in this set, i.e., 15, 16, 17, and 18, were isolated. It was purified by crystallization from a mixture of Et$_2$O and CHCl$_3$, affording 5 (258 mg) as a white solid. mp = 149°C - 150°C. IR (KBr): 1609, 1698, 3126, 3225, 3481. $^1$H NMR (CD$_3$OD) $\delta$: 1.21 (t, $^3$J = 6.7 Hz, CH$_3$); 3.28 (t, $^3$J = 6.8 Hz, CH$_2$). Anal.Calcd. for C$_4$H$_8$N$_4$O$_2$: C, 27.27; H, 6.10; N, 42.41. Found: C, 27.13; H, 5.78; N, 42.15.

1-ethyl-3-nitroguanidine (1):

Ethylamine (0.235 mL, 3.60 mmol) was added dropwise, at 10°C, to a suspension of 1-methyl-3-nitro-1-nitrosoguanidine (529 mg, 3.60 mmol) in a mixture of ethanol and water (50/50, v/v, 8 mL). After 24 h at room temperature, the reaction mixture was quenched by addition of 10 mL of NaOH (1N) and 10 mL of saturated aqueous ammonium chloride. Overall (468 mg, 86%) of 1 was isolated. It was purified by crystallization from a mixture of Et$_2$O and CHCl$_3$, affording 1 as a white solid, mp = 109°C - 110°C. IR (KBr): 1552, 1603, 1651, 3165, 3309, 3391. $^1$H NMR (CD$_3$OD) $\delta$: 1.34 - 1.45 (m, CH$_2$); 3.19 (t, $^3$J = 7.1 Hz, CH$_2$). Anal.Calcd. for C$_3$H$_8$N$_4$O$_2$: C, 27.76; H, 6.74; N, 38.53. Found: C, 27.72; H, 6.74; N, 38.52.

1-butyl-3-nitroguanidine (3):

Butylamine (0.35 mL, 3.50 mmol) was added dropwise to a suspension of 1-methyl-3-nitro-1-nitrosoguanidine (501 mg, 3.41 mmol) in a mixture of ethanol and water (50/50, v/v, 13 mL). After 24 h at room temperature, the product that precipitated out of solution was isolated by suction filtration, washed with cold water and dried with the assistance of P$_2$O$_5$ affording 3 (822 mg, 65%) as a white solid, mp = 109°C. IR (KBr): 1605, 1698, 3126, 3225, 3481. $^1$H NMR (CD$_3$OD) $\delta$: 1.34 - 1.45 (m, CH$_2$); 3.19 (t, $^3$J = 7.1 Hz, CH$_2$). Anal.Calcd. for C$_4$H$_8$N$_4$O$_2$: C, 38.53; H, 7.78; N, 38.53. Found: C, 38.52; H, 7.78; N, 38.52.
a white solid. mp = 145.5°C - 146.5°C. IR (KBr): 1562, 1600, 1642, 3122, 3246, 3398. 1H NMR (CD3OD) δ:
4.02 (q, 3JHF = 9.05 Hz, CH3). Anal.Calcd. for C24H23F2N5O4: C, 38.76; H, 3.04; N, 22.38. Found: C, 38.80; H, 3.00; N, 22.41.

1-nitro-3-(2,2,3,3,3-pentafluoropropyl)guanidine (5):
2,2,3,3,3-pentafluoropropylamine (0.48 mL, 3.10 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (419 mg, 3.39 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (477 mg, 78%) of the title compound.

1-nitro-3-(2-fluoro-6-amino-benzyl)guanidine (6):
The title compound was prepared according to the above procedure using 2-fluoro-6-amino-benzylamine (352 mg, 2.14 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (336 mg, 2.29 mmol) in a mixture of ethanol and water (50/50, v/v, 10 mL). The reaction afforded (345 mg, 67%) of the title compound.

1-nitro-3-(2,2,3,3,3,4,4,4-heptafluorobutyl)-2-nitro-guanidine (7):
The title compound was prepared according to the above procedure using 2,2,3,3,3,4,4,4-heptafluorobutylamine (0.45 mL, 3.16 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (471 mg, 3.20 mmol) in a mixture of ethanol and water (50/50, v/v, 12 mL). The reaction afforded (794 mg, 95%) of the title compound.

1-nitro-3-(2-amino-6-fluorobenzyl)-3-nitroguanidine (8):
The title compound was prepared according to the above procedure using 2-((trifluoromethyl)benzyl)amine (0.48 mL, 3.10 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (455 mg, 3.44 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (477 mg, 78%) of the title compound.

1-nitro-3-(2-(trifluoromethyl)benzyl)amine (9):
The title compound was prepared according to the above procedure using 2-(trifluoromethyl)benzylamine (0.48 mL, 3.10 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (449 mg, 3.39 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (711 mg, 86%) of the title compound.

1-benzyl-3-nitroguanidine (10):
The title compound was prepared according to the above procedure using benzylamine (0.40 mL, 3.65 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (533.5 mg, 3.62 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (628 mg, 95%) of the title compound.

1-nitro-3-(3-(trifluoromethyl)benzyl)guanidine (11):
The title compound was prepared according to the above procedure using 3-(trifluoromethyl)benzylamine (0.50 mL, 3.49 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (510 mg, 3.47 mmol) in a mixture of ethanol and water (50/50, v/v, 16 mL). The reaction afforded (794 mg, 88%) of the title compound.

1-(2-amino-6-fluorobenzyl)-3-nitroguanidine (12):
The title compound was prepared according to the above procedure using 2-fluoro-6-amino-benzylamine (352 mg, 2.14 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (336 mg, 2.29 mmol) in a mixture of ethanol and water (50/50, v/v, 10 mL). The reaction afforded (345 mg, 67%) of the title compound.
C. D. Guillon et al.

(13): The title compound was prepared according to the above procedure using 2-aminomethyl-thiophene (0.36 mL, 3.50 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (515 mg, 3.50 mmol) in a mixture of ethanol and water (50/50, v/v, 16 mL). The reaction afforded (577 mg, 84%) of (13) as a white solid. mp = 174° C - 175.5° C. IR (KBr): 1553, 1594, 1650, 3181, 3302, 3381. \( ^1H \text{NMR} \) (CD\(_3\)OD) \( \delta \): 4.62 (s, CH\(_2\)); 7.46 (d, \( J = 3.8 \) Hz, \( CH_2 \)); 7.70 (d, \( J = 5.0 \) Hz, S-CH=). \textbf{Anal.Caled.} for C\(_8\)H\(_9\)N\(_5\)O\(_2\): C, 45.95; H, 5.37; N, 33.29.

1-nitro-3-(thiophen-2-ylmethyl)guanidine(14):

1-nitro-3-(2-thiophen-2-yl)ethyl)guanidine(15):

3-amino-pyridine (330 mg, 3.51 mmol) was added to a suspension of 1-methyl-3-nitro-1-nitrosoguanidine (1.144 g, 7.73 mmol) in a mixture of ethanol and water (50/50, v/v, 16 mL). The reaction afforded (577 mg, 84%) of (14) as a white solid. mp = 194.5° C - 195° C. IR (KBr): 1541, 1597, 1650, 3167, 3318, 3378. \( ^1H \text{NMR} \) (CD\(_3\)OD) \( \delta \): 7.01 (d, J = 8.4 Hz, H3); 7.08 (dd, J\(_2\) = 7.5 Hz, J\(_1\) = 7.1 Hz, J\(_\alpha\) = 0.7 Hz, H5); 7.74 (dd, J\(_1\) = 9.1 Hz, J\(_2\) = 7.4 Hz, J\(_\alpha\) = 1.8 Hz, H4); 8.28 (dd, J\(_1\) = 5.1 Hz, J\(_\alpha\) = 1.7 Hz, J\(_\beta\) = 0.7 Hz, H6). \textbf{Anal.Caled.} for C\(_9\)H\(_{10}\)N\(_5\)O\(_2\): C, 39.24; H, 4.70; N, 26.15. Found: C, 39.26; H, 4.50; N, 26.02.

The title compound was prepared according to the above procedure using 2-(2-aminoethyl)-thiophene (984 mg, 7.73 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (1.144 g, 7.73 mmol) in a mixture of ethanol and water (50/50, v/v, 10 mL). The mixture was reacted overnight at 90° C - 95° C. The reaction mixture was dry evaporated and the crude product purified by flash chromatography (silica gel, CHCl\(_3\) (90%)MeOH (10%)). The expected compound 15 was isolated as a white solid (91 mg, 14%). mp = 160° C - 161° C. \textbf{IR} (KBr): 1555, 1588, 1636, 3074, 3219, 3328. \( ^1H \text{NMR} \) (CD\(_3\)OD) \( \delta \): 7.46 (dd, J\(_1\) = 8.1 Hz, J\(_2\) = 5.0 Hz, H3); 7.90 (d, J\(_\alpha\) = 8.2 Hz, HJ = 1.4 Hz, H4); 8.37 (d, J\(_\alpha\) = 4.8 Hz, J\(_\alpha\) = 1.3 Hz, H5); 8.52 (d, J\(_\alpha\) = 2.2 Hz, H2). \textbf{Anal.Caled.} for C\(_9\)H\(_{10}\)N\(_5\)O\(_2\): C, 39.78; H, 3.89; N, 38.66. Found: C, 39.35; H, 3.71; N, 38.81.

1-nitro-3-(pyridin-3-yl)methyl)guanidine(16):

2-amino-pyridine (361 mg, 3.84 mmol) was added to a suspension of 1-methyl-3-nitro-1-nitrosoguanidine (516 mg, 3.51 mmol) in a mixture of ethanol and water (50/50, v/v, 10 mL). The mixture was reacted 2 h at 60° C and overnight at 90° C. The reaction mixture was dry evaporated and the crude product purified by flash chromatography (silica gel, CHCl\(_3\) (95%)/MeOH (5%)). The expected compound 16 was isolated as a yellowish solid (45 mg, 7%). It was further purified by crystallization from MeOH to afford a white solid. mp = 226° C - 227° C. \textbf{IR} (KBr): 1543, 1559, 1600, 1610, 3160 - 3600. \( ^1H \text{NMR} \) (CD\(_3\)OD) \( \delta \): 7.01 (d, J = 8.4 Hz, H3); 7.08 (dd, J\(_2\) = 7.5 Hz, J\(_1\) = 7.1 Hz, J\(_\alpha\) = 0.7 Hz, H5); 7.74 (ddd, J\(_1\) = 9.1 Hz, J\(_2\) = 7.4 Hz, J\(_\alpha\) = 1.8 Hz, H4); 8.28 (ddd, J\(_1\) = 5.1 Hz, J\(_\alpha\) = 1.7 Hz, J\(_\beta\) = 0.7 Hz, H6). \textbf{Anal.Caled.} for C\(_8\)H\(_9\)N\(_4\)O\(_2\): C, 38.82; H, 4.07; N, 37.72. Found: C, 38.88; H, 3.85; N, 37.51.

1-nitro-3-(pyridin-3-yl)ethyl)guanidine(17):

The title compound was prepared according to the above procedure (compound 5) using 2-aminomethyl-pyridine (0.35 mL, 3.40 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (500 mg, 3.40 mmol) in a mixture of ethanol and water (50/50, v/v, 9 mL). The reaction afforded (607 mg, 92%) of 17 as a white solid. 17 (607 mg, 92%). It was purified by crystallization from MeOH to afford a white yellowish solid. mp = 142° C - 142.5° C. \textbf{IR} (KBr): 1570, 1592, 1612, 1632, 3117, 3186, 3245, 3342. \( ^1H \text{NMR} \) (CD\(_3\)OD) \( \delta \): 3.06 (t, J\(_1\) = 6.8 Hz, CH\(_2\)); 3.61 (t, J\(_1\) = 7.0 Hz, CH\(_2\)); 7.28 (dd, J\(_1\) = 7.1 Hz, J\(_\alpha\) = 5.2 Hz, H4); 7.35 (d, J\(_1\) = 7.8 Hz, H5); 7.77 (ddd, J\(_1\) = J\(_\alpha\) = 7.7 Hz, J\(_\beta\) = 1.7 Hz, H6); 8.49 (d, J\(_2\) = 4.4 Hz, H5). \textbf{Anal.Caled.} for C\(_8\)H\(_9\)N\(_4\)O\(_2\): C, 45.93; H, 5.30; N, 33.48. Found: C, 45.95; H, 5.37; N, 33.29.

N-nitropiperidine-1-carboximidamide(19):
The title compound was prepared according to the above procedure (compound 5) using piperidine (0.35 mL, 3.54 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (510 g, 3.47 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (340 mg, 57%) of 19 as a white solid. mp = 151°C - 153°C. IR (KBr): 1562, 1615, 3210, 3263, 3362. **1H NMR** (CD3OD): δ: 1.19 - 1.23 (m, 1H, C(H)H); 1.70 - 1.75 (m, 5H, CH2); 2.50 - 2.56 (m, 2H, CH2); 2.93 - 2.99 (m, 2H, CH2). **Anal.Calcd.** for C6H12N4O2: C, 41.85; H, 7.02; N, 32.54. Found: C, 41.95; H, 7.05; N, 32.48.

1-nitro-3-(piperidin-1-yl)guanidine (20):

The title compound was prepared according to the above procedure (compound 5) using 1-aminopiperidine (0.34 mL, 3.15 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (460 g, 3.13 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (216 mg, 37%) of 19 as a white solid. mp = 101°C. IR (KBr): 1582, 1621, 3215, 3267, 3418. **1H NMR** (CD3OD): δ: 1.46 - 1.49 (m, CH2); 1.57 - 1.64 (m, CH2); 2.48/2.52/2.56 (s and m, CH2); 3.35 (t, J = 5.9 Hz, CH2). **Anal.Calcd.** for C6H12N4O2: C, 54.54; H, 5.49; N, 37.18. Found: C, 54.48; H, 5.37; N, 37.52.

1-nitro-3-(piperidin-1-yl)guanidine (21):

The title compound was prepared according to the above procedure (compound 5) using 1-(2-aminoethyl)piperidine (0.515 mL, 3.61 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (529 mg, 3.59 mmol) in a mixture of ethanol and water (50/50, v/v, 9 mL) affording (634 mg, 81%) of 21 as a white solid. mp = 168°C - 168.5°C. IR (KBr): 1543, 1586, 1641, 3119, 3239, 3367. **1H NMR** (CD3OD): δ: 1.19 - 1.23 (m, 1H, C(H)H); 1.70 - 1.75 (m, 5H, CH2); 2.50 - 2.56 (m, 2H, CH2); 2.93 - 2.99 (m, 2H, CH2). **Anal.Calcd.** for C6H12N4O2: C, 41.85; H, 7.02; N, 32.54. Found: C, 41.95; H, 7.05; N, 32.48.

1-nitro-3-(piperidin-1-yl)guanidine (22):

The title compound was prepared according to the above procedure (compound 5) using 2-isoquinoline (0.39 mL, 3.12 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (466 mg, 3.17 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL) affording (587 mg, 89%) of 22 as a white solid. mp = 119.5°C - 121°C. IR (KBr): 1571, 1610, 3260, 3386. **1H NMR** (CD3OD): δ: 2.94 (t, J = 6.0 Hz, CH2); 3.74 (t, J = 6.0 Hz, CH2); 6.68 (s, CH2); 7.16 - 7.23 (m, 4H, -CH=). **Anal.Calcd.** for C6H12N4O2: C, 54.54; H, 5.49; N, 37.24. Found: C, 54.55; H, 5.37; N, 37.52.

N-nitromorpholine-4-carboximidamide (23):

The title compound was prepared according to the above procedure (compound 5) using morpholine (0.28 mL, 3.20 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (466 mg, 3.15 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL) affording (404 mg, 78%) of 23 as a white solid. mp = 168.5°C - 169°C. IR (KBr): 1560, 1612, 3289, 3401. **1H NMR** (CD3OD): δ: 3.57 (t, J = 4.9 Hz, N-CH2); 3.69 (t, J = 4.9 Hz, O-CH2). **Anal.Calcd.** for C6H12N4O2: C, 34.48; H, 5.79; N, 32.17. Found: C, 34.39; H, 5.44; N, 32.46.

1-morpholin-3-nitroguanidine (24):

The title compound was prepared according to the above procedure (compound 5) using 1-aminomorpholine (0.32 mL, 3.22 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (492 g, 3.34 mmol) in a mixture of ethanol and water (50/50, v/v, 14 mL). The reaction afforded (240 mg, 68%) of 24 as a white solid. mp = 243°C, decomposition. IR (KBr): 1582, 1621, 3215, 3267, 3418. **1H NMR** (CD3OD): δ: 2.75 - 2.90 (m, 4H, O-CH2); 3.30 - 3.65 (m, 4H, NCH2). **Anal.Calcd.** for C6H14N5O2: C, 31.75; H, 5.86; N, 37.02. Found: C, 32.14; H, 5.62; N, 36.89.

3-morpholinono-N-nitropropanamidine (25):

The title compound was prepared according to the above procedure (compound 5) using 4-((2-aminoethyl)morpholine (0.49 mL, 3.73 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (543 mg, 3.69 mmol) in a mixture of ethanol and water (50/50, v/v, 9 mL) affording (633 mg, 79%) of 25 as a white solid. mp = 190.5°C - 191.5°C. IR (KBr): 1581, 1655, 3114, 3236, 3367. **1H NMR** (CD3OD): δ: 2.51/2.58 (s and s, CH2); 3.37 (t, J = 5.9 Hz, CH2); 3.70 (t, J = 4.6 Hz, CH2). **Anal.Calcd.** for C6H15N5O2: C, 38.70; H, 6.96; N, 32.24. Found: C, 38.74; H, 6.82; N, 32.17.

1-nitro-3-((tetrahydrothiophen-2-yl)methyl)guanidine (26):

The title compound was prepared according to the above procedure (compound 5) using tetrahydrothiophurinylamine (0.36 mL, 3.49 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (510 g, 3.47 mmol) in a mixture of ethanol and water (50/50, v/v, 9 mL) affording (527 mg, 79%) of 26 as a white solid. mp = 84°C - 85°C. IR (KBr): 1603, 1645, 3123, 3177, 3245, 3399. **1H NMR** (CD3OD): δ: 1.63 - 1.72/1.85 - 2.02 (m and m, 4H, H2/2/3/3); 3.36 (dt, J1 = 15.1 Hz, J2 = 5.9 Hz, H2); 3.61 (dd, J1 = 15.1 Hz, J3 = 3.2 Hz, J4 = 1.65 Hz, H4); 3.75 (dd, J5 = 13.4 Hz, J6 = 6.8 Hz, CH2); 3.86 (dd, J5 = 14.9 Hz, J7 = 6.8 Hz, CH2); 4.00 - 4.08 (m, H1). **Anal.Calcd.** for C6H12N4O2: C, 38.30; H, 6.43; N, 29.77. Found: C, 38.05; H, 6.40; N, 29.54.
1-nitro-3-(thiophen-2-ylmethyl)guanidine (27):

The title compound was prepared according to the above procedure (compound 5) using furfurylamine (0.31 mL, 3.51 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (500 mg, 3.40 mmol) in a mixture of ethanol and water (50/50, v/v, 9 mL) affording (388 mg, 62%) of 27 as a white solid. mp = 138.5°C - 140°C. IR (KBr): 1544, 1594, 1652, 3175, 3322, 3387. $^1$H NMR (CD$_3$OD) δ: 4.36 (s, 2H, CH$_2$); 6.33 - 6.37 (m, 2H, -CH=); 7.46 (s, 1H, -CH=). Anal.Calcd. for C$_6$H$_8$N$_4$O$_3$: C, 39.13; H, 4.38; N, 30.42. Found: C, 39.04; H, 4.32; N, 30.33.

1-((5-methylthiophen-2-yl)methyl)-3-nitroguanidine (28):

The title compound was prepared according to the above procedure (compound 5) using 5-methylfurfurylamine (0.44 mL, 3.95 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (573 mg, 3.90 mmol) in a mixture of ethanol and water (50/50, v/v, 9 mL) affording (700 mg, 91%) of 28 as an off white solid. mp = 162.5°C - 163°C. IR (KBr): 1549, 1602, 1651, 3161, 3306, 3381. $^1$H NMR (CD$_3$OD) δ: 2.25 (s, CH$_3$); 4.37 (s, CH$_2$); 5.94 (d, $^3$J = 2.1 Hz, CH); 6.20 (d, $^3$J = 2.6 Hz, CH). Anal.Calcd. for C$_7$H$_{10}$N$_4$O$_3$: C, 42.42; H, 5.09; N, 28.27. Found: C, 42.45; H, 4.92; N, 28.05.

N-nitropyrrolidine-1-carboximidamide (29):

The title compound was prepared according to the above procedure (compound 5) using ppyrrolidine (0.30 mL, 3.59 mmol) and 1-methyl-3-nitro-1-nitrosoguanidine (520 mg, 3.54 mmol) in a mixture of ethanol and water (50/50, v/v, 12 mL). The reaction afforded (375 mg, 67%) of 29 as a white solid. mp = 188°C - 189°C. IR (KBr): 1563, 1617, 3218, 3279, 3431. $^1$H NMR (CD$_3$OD) δ: 1.94 - 2.00 (m, 4H, CH$_2$); 3.41 -3.47 (m, 4H, CH$_2$). Anal.Calcd. for C$_5$H$_{10}$N$_4$O$_2$: C, 37.97; H, 6.37; N, 35.42. Found: C, 38.10; H, 6.44; N, 35.63.

1-nitro-3-(2-(pyrrolidin-1-yl)ethyl)guanidine (30):

The title compound was prepared according to the above procedure (compound 5) using 1-(2-aminoethyl)pyrrolidine (0.48 mL, 3.79 mmol), 1-methyl-3-nitro-1-nitrosoguanidine (549 mg, 3.73 mmol) in absolute ethanol (6 mL) affording, after cooling at $-10^\circ$C, (250 mg, 33%) of 30 as a white solid. mp = 119°C - 120°C. IR (KBr): 1544, 1593, 1640, 3119, 3236, 3361. $^1$H NMR (CD$_2$OD) δ: 1.79 - 1.83 (m, CH$_2$); 2.60/2.71 (s and s, CH$_2$); 3.78 (t, $^3$J = 6.2 Hz, CH$_2$). Anal.Calcd. for C$_7$H$_{15}$N$_5$O$_2$: C, 41.78; H, 7.51; N, 34.80. Found: C, 41.90; H, 7.46; N, 34.74.

4.2. Biology

Assay for Nitric Oxide Synthase activity: Compounds were assayed for nitric oxide synthase activity using a citrulline formation assay with affinity purified enzymes and L-[2,3-3H]arginine as the substrate [23]. Enzymes were prepared as previously described [24]. For enzyme assays, iNOS, eNOS or nNOS was incubated in 150 μL reaction mixtures containing 30 mM Hepes (pH 7.5), 1 mM EGTA, 1 mM dithiothreitol, 120 nM L-[2,3-3H]arginine (New England Nuclear, final concentration 200,000 dpm/reaction mix), 100 μM NADPH, and 300 μM tetrahydrobiopterin. For assays with nNOS and eNOS, 6 μM calmodulin and 0.85 mM Ca$^{2+}$ were also added. Reactions, run in duplicate in 5 ml glass scintillation vials, were initiated by the addition of iNOS, eNOS or nNOS with and without increasing concentrations of the inhibitors. After 30 min at 30°C, reactions were stopped by the addition of 1 ml of AF 50WX8 resin in 20 mM Mes (pH 5.5) containing 2 mM EDTA. Four ml of scintillation fluid (Ecolite, Fisher Scientific) were then added with rapid mixing. The resin was allowed to settle and the reaction vials were then counted for radioactivity. Blank control samples contained all reaction components except nitric oxide synthase and were routinely 2% - 3% of the added radioactivity. In this assay, unreacted $^3$H-arginine binds to the resin and is completely quenched. Formation of citrulline was calculated from the known specific activity of arginine. Data are presented as the concentration of compound inhibiting iNOS, eNOS or nNOS by 50%.

Acknowledgements

This work was funded in part by the National Institutes of Health CounterACT Program through the National Institute of Arthritis and Musculoskeletal and Skin Disease (award # U54AR055073). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the US federal government.

References


